In this systematic review and meta-analysis including 42 head-to-head comparative effectiveness studies of 813 881 patients with IMIDs treated with JAK inhibitors or TNF antagonists, no meaningful differences in risk of serious infections, malignant neoplasms, and major cardiovascular events were observed. The gene discussed is TNF; the disease is cancer.